Kim, S Y
Theunissen, J-W
Balibalos, J
Liao-Chan, S
Babcock, M C
Wong, T
Cairns, B
Gonzalez, D
van der Horst, E H
Perez, M
Levashova, Z
Chinn, L
D‘Alessio, J A
Flory, M
Bermudez, A
Jackson, D Y
Ha, E
Monteon, J
Bruhns, M F
Chen, G
Migone, T-S
Article History
Received: 1 April 2015
Accepted: 17 April 2015
First Online: 29 May 2015
Competing interests
: All authors are employees of Igenica Biotherapeutics. Igenica Biotherapeutics is a company funded by venture capital firms – The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures.